Trastuzumab

Red

Brand Name(s):Herceptin
Ontruzant
Herzuma
Kanjinti

Indication:HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction

Rationale:1,2,3

Considered:Mar-10

Review Date:Jun-23

Comments:
1.1 Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an option for the treatment of people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who: have not received prior treatment for their metastatic disease and have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3 (IHC3 positive).

1.2 People who are currently receiving treatment with trastuzumab for HER2-positive metastatic gastric cancer who do not meet the criteria in 1.1 should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

NICE TA 208
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
November 2010